Search | Influenza A(H1N1)

  • BIREME | OPAS | OMS logo
 

Search history  ()

Send by email

You have 0 documents selected.

No documents was selected

 
Results  1-12 de 364
1.

Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.

Author(s): Ilyushina, Natalia A; Komatsu, Takashi E; Ince, William L; Donaldson, Eric F; Lee, Nicolette; O'Rear, Julian J; Donnelly, Raymond P
Source: Virol J;16(1): 149, 2019 11 29.
MEDLINE - International Database for Medical Literature PMID: 31783761
Abstract: BACKGROUND: Vaccination and the use of neuraminidase inhibitors (NAIs) are currently the front lines of defense against seasonal influenza. The activity of influenza vaccines and antivirals drugs such as the NAIs can be affected by mutations in the influenza hemagglutinin (HA) protein. Numerous HA substitutions have been identified in nonclinical NAI resistance-selection experiments as well as in clinical specimens from NAI treatment or surveillance studies. These mutations are listed in th (more)
2.

Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series.

Author(s): Torti, Carlo; Mazzitelli, Maria; Longhini, Federico; Garofalo, Eugenio; Bruni, Andrea; Giancotti, Aida; Barreca, Giorgio Settimo; Quirino, Angela; Liberto, Maria Carla; Serapide, Francesca; Matera, Giovanni; Trecarichi, Enrico Maria; Navalesi, Paolo
Source: BMC Infect Dis;19(1): 858, 2019 Oct 16.
MEDLINE - International Database for Medical Literature PMID: 31619209
Abstract: BACKGROUND: Intravenous (IV) zanamivir could be a suitable alternative for the treatment of severe influenza A(H1N1)pdm09 infection in patients who are unable to take oral or inhaled medication, for example, those on mechanical ventilation and extracorporeal membrane oxygenation (ECMO). However, data on the clinical outcomes of such patients is limited. CASE PRESENTATION: We report the clinical outcomes of four patients who were admitted at the intensive care unit during the 2017-2018 influ (more)
3.

Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.

Author(s): Tomozawa, Takanori; Hoshino, Kazuki; Yamashita, Makoto; Kubo, Shuku
Source: J Infect Chemother;25(8): 584-588, 2019 Aug.
MEDLINE - International Database for Medical Literature PMID: 30935767
Abstract: Four neuraminidase (NA) inhibitors and an RNA synthesis inhibitor were recently approved and are currently in clinical use for influenza. Among NA inhibitors, oseltamivir phosphate (OSE, Tamiflu®) and zanamivir are approved worldwide, whereas peramivir and laninamivir octanoate (LAN, Inavir®) are regionally approved for human use. Therefore, OSE has been used to treat infections of highly pathogenic influenza viruses, such as H5N1 and H7N9, which caused epidemic in southeast Asia and Egyp (more)
4.

Antiviral treatment and virological monitoring of oseltamivir-resistant influenza virus A(H1N1)pdm09 in a patient with chronic B lymphocytic leukemia.

Author(s): Salata, Cristiano; Sgarabotto, Dino; Del Vecchio, Claudia; Solimbergo, Erica; Marini, Giulia; Nicolè, Stefano; Franchin, Elisa; Parolin, Cristina; Calistri, Arianna; Palù, Giorgio
Source: J Infect Chemother;25(7): 543-546, 2019 Jul.
MEDLINE - International Database for Medical Literature PMID: 31014561
Abstract: We report the virological monitoring and the antiviral therapy adopted for the treatment of a patient affected by chronic B lymphocytic leukemia, who experienced a severe pneumonia with long-term shedding of influenza virus A(H1N1)pdm09, characterized by an early development of oseltamivir resistance.
5.

In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection.

Author(s): Lloren, Khristine Kaith S; Kwon, Jin Jung; Choi, Won-Suk; Jeong, Ju Hwan; Ahn, Su Jeong; Choi, Young Ki; Baek, Yun Hee; Song, Min-Suk
Source: J Virol;93(6)2019 03 15.
MEDLINE - International Database for Medical Literature PMID: 30602610
Abstract: Neuraminidase (NA) inhibitors (NAIs) are widely used antiviral drugs for the treatment of humans with influenza virus infections. There have been widespread reports of NAI resistance among seasonal A(H1N1) viruses, and most have been identified in oseltamivir-exposed patients or those treated with other NAIs. Thus, monitoring and identifying NA markers conferring resistance to NAIs-particularly newly introduced treatments-are critical to the management of viral infections. Therefore, we scr (more)
6.

Replacement of neuraminidase inhibitor-susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa.

Author(s): Treurnicht, Florette K; Buys, Amelia; Tempia, Stefano; Seleka, Mpho; Cohen, Adam L; Walaza, Sibongile; Glass, Allison J; Rossouw, Inéz; McAnerney, Johanna; Blumberg, Lucille; Cohen, Cheryl; Venter, Marietjie
Source: Influenza Other Respir Viruses;13(1): 54-63, 2019 01.
MEDLINE - International Database for Medical Literature PMID: 30218485
Abstract: BACKGROUND: Data on the susceptibility of influenza viruses from South Africa to neuraminidase inhibitors (NAIs) are scarce, and no extensive analysis was done. OBJECTIVES: We aimed to determine oseltamivir and zanamivir susceptibility of influenza A and B virus neuraminidases (NAs), 2007-2013, South Africa. PATIENTS/METHODS: We enrolled participants through national influenza-like illness surveillance, 2007-2013. Influenza diagnosis was by virus isolation and quantitative polymerase chain (more)
7.

Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.

Author(s): Cheng, Li Ping; Wang, Tian Chi; Yu, Rao; Li, Meng; Huang, Jin Wen
Source: Bioorg Med Chem Lett;28(23-24): 3622-3629, 2018 12 15.
MEDLINE - International Database for Medical Literature PMID: 30389293
Abstract: Neuraminidase (NA) is an important antiviral drug target. Zanamivir is one of the most potent NA inhibitors. In this paper, a series of zanamivir derivatives as potential NA inhibitors were studied by combination of molecular modeling techniques including 3D-QSAR, molecular docking, and molecular dynamics (MD) simulation. The results show that the best CoMFA (comparative molecular field analysis) model has q2 = 0.728 and r2 = 0.988, and the best CoMSIA (comparative molec (more)
8.

Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.

Author(s): Pichon, Maxime; Picard, Caroline; Simon, Bruno; Gaymard, Alexandre; Renard, Cécile; Massenavette, Bruno; Malcus, Christophe; Monneret, Guillaume; Morfin-Sherpa, Florence; Valette, Martine; Javouhey, Etienne; Millat, Gilles; Lina, Bruno; Josset, Laurence; Escuret, Vanessa
Source: Antiviral Res;160: 1-9, 2018 12.
MEDLINE - International Database for Medical Literature PMID: 30315875
Abstract: INTRODUCTION: A child with severe combined immunodeficiency (SCID) had an influenza A(H1N1)pdm09 infection with viral excretion longer than 6 months, during 2013-2014 influenza season, despite cord blood transplantation and antiviral treatments. METHODS: Conventional real-time RT-PCR methods were used to estimate viral load and to detect the presence of the common N1 neuraminidase (NA) H275Y substitution responsible for oseltamivir resistance. Next-generation sequencing (NGS) of influenza v (more)
9.

Treatment of influenza with neuraminidase inhibitors.

Author(s): Beard, Kate R; Brendish, Nathan J; Clark, Tristan W
Source: Curr Opin Infect Dis;31(6): 514-519, 2018 12.
MEDLINE - International Database for Medical Literature PMID: 30320639
Abstract: PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globally. Neuraminidase inhibitors (NAIs) are the only class of antiviral agent recommended for the treatment of currently circulating strains of influenza. There has previously been controversy over the level of evidence for patient benefit with NAIs. We review here the current evidence base for the clinical impact of treatment of influenza with NAIs. RECENT FINDINGS: Meta-analysis of pharma-spon (more)
10.

A Small-Molecule Compound Has Anti-influenza A Virus Activity by Acting as a ''PB2 Inhibitor".

Author(s): Liu, Teng; Liu, Miaomiao; Chen, Feimin; Chen, Fangzhao; Tian, Yuanxin; Huang, Qi; Liu, Shuwen; Yang, Jie
Source: Mol Pharm;15(9): 4110-4120, 2018 09 04.
MEDLINE - International Database for Medical Literature PMID: 30102858
Abstract: With regular influenza epidemics and the prevalence of drug-resistant influenza virus strains, it is extremely crucial to develop effective and low-toxicity anti-influenza A virus drugs that act on conserved sites of novel targets. Here, we found a new anti-influenza virus compound, 1,3-dihydroxy-6-benzo[ c]chromene (D715-2441), from a library of 8026 small-molecule compounds by cell-based MTT assay and explored the underlying mechanisms. Our results revealed that D715-2441 possessed antivi (more)
11.

Antigenic and genetic characterization of influenza viruses isolated in Mozambique during the 2015 season.

Author(s): Tivane, Almiro; Daniels, Rodney; Nguenha, Neuza; Machalele, Loira; Nacoto, Afonso; Pale, Mirela; Mateonane, Edirsse; Mavale, Sandra; Chilundo, Josina; Muteto, Délcio; Salência, Judite; Albati, Félix; Gudo, Eduardo; Mussá, Tufária; McCauley, John
Source: PLoS One;13(7): e0201248, 2018.
MEDLINE - International Database for Medical Literature PMID: 30048502
Abstract: BACKGROUND: Due to the high rate of antigenic variation of influenza virus, seasonal characterization of the virus is crucial to assess and monitor the emergence of new pathogenic variants and hence formulate effective control measures. However, no study has yet been conducted in Mozambique to assess genetic, antigenic and antiviral susceptibility profile of influenza virus. METHODS: A subset of samples (n = 20) from influenza positive children detected in two hospitals in Maputo city durin (more)
12.

Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.

Author(s): Ikematsu, Hideyuki; Kawai, Naoki; Iwaki, Norio; Kashiwagi, Seizaburo; Ishikawa, Yusuke; Yamaguchi, Hiroki; Shiosakai, Kazuhito
Source: J Infect Chemother;24(9): 718-724, 2018 Sep.
MEDLINE - International Database for Medical Literature PMID: 29861186
Abstract: The duration of fever and symptoms after laninamivir octanoate hydrate (laninamivir) inhalation were investigated in the Japanese 2016/17 influenza season and the results were compared with those of the 2011/12 to 2015/16 seasons. A total of 1278 patients were evaluated for the duration of fever and symptoms in the six studied seasons. In the 2016/17 season, the influenza types/subtypes of the patients were 6 A (H1N1)pdm09 (2.9%), 183 A (H3N2) (87.6%), and 20 B (9.6%). The respective media (more)
Results  1-12 de 364